Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT

Background Comprehensive data from prospective clinical trials have led to a high level of evidence establishing CDK4/6 inhibitors in combination with endocrine treatment (CDK4/6i + ET) as a standard for the treatment of HER2-negative, hormone receptor-positive (HER2− HR+) breast cancer patients in...

Descripción completa

Detalles Bibliográficos
Autores principales: Engler, Tobias, Fasching, Peter A., Lüftner, Diana, Hartkopf, Andreas D., Müller, Volkmar, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Häberle, Lothar, Ettl, Johannes, Wallwiener, Markus, Beckmann, Matthias W., Hein, Alexander, Belleville, Erik, Uhrig, Sabrina, Wimberger, Pauline, Hielscher, Carsten, Kurbacher, Christian M., Wuerstlein, Rachel, Untch, Michael, Taran, Florin-Andrei, Enzinger, Hans-Martin, Krabisch, Petra, Welslau, Manfred, Maasberg, Michael, Hempel, Dirk, Lux, Michael P., Michel, Laura L., Janni, Wolfgang, Wallwiener, Diethelm, Brucker, Sara Y., Fehm, Tanja N., Schneeweiss, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525148/
https://www.ncbi.nlm.nih.gov/pubmed/36186151
http://dx.doi.org/10.1055/a-1880-0087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525148/
https://www.ncbi.nlm.nih.gov/pubmed/36186151
http://dx.doi.org/10.1055/a-1880-0087

Ejemplares similares